Key Points
- BeOne Medicines COO Xiaobin Wu sold 280 shares at an average price of $380, generating $106,400 under a pre-arranged Rule 10b5-1 trading plan. Wu has also reported several earlier sales in June.
- ONC shares opened at $372.49 and were down 0.9%, with the stock near its one-year high of $385.22. BeOne reported quarterly EPS of $2.05, exceeding estimates of $1.40, while revenue reached $1.71 billion.
- Analysts maintain a generally positive outlook, with an average rating of “Buy” and an average price target of $402.14; 48.55% of the company’s shares are held by institutional investors.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 280 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $380.00, for a total transaction of $106,400.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, June 23rd, Xiaobin Wu sold 1,292 shares of BeOne Medicines stock. The shares were sold at an average price of $276.26, for a total value of $356,927.92.
- On Tuesday, June 16th, Xiaobin Wu sold 1,357 shares of BeOne Medicines stock. The shares were sold at an average price of $266.76, for a total transaction of $361,993.32.
- On Thursday, June 11th, Xiaobin Wu sold 626 shares of BeOne Medicines stock. The stock was sold at an average price of $261.20, for a total transaction of $163,511.20.
- On Monday, June 8th, Xiaobin Wu sold 1,484 shares of BeOne Medicines stock. The shares were sold at an average price of $269.37, for a total value of $399,745.08.
BeOne Medicines Trading Down 0.9%
ONC stock opened at $372.49 on Friday. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $253.95 and a one year high of $385.22. The company has a market capitalization of $40.90 billion, a PE ratio of 65.58 and a beta of 0.49. The company's 50 day moving average price is $323.60 and its two-hundred day moving average price is $310.92. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The firm had revenue of $1.71 billion for the quarter, compared to analysts' expectations of $1.66 billion. As a group, analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 8.81 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts have commented on the stock. Zacks Research upgraded shares of BeOne Medicines from a "hold" rating to a "strong-buy" rating in a report on Friday, August 7th. TD Cowen raised their price objective on BeOne Medicines from $424.00 to $454.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Citigroup reiterated an "outperform" rating on shares of BeOne Medicines in a research note on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of BeOne Medicines in a research note on Friday, July 17th. Finally, Wells Fargo & Company assumed coverage on BeOne Medicines in a report on Monday, May 4th. They set an "overweight" rating and a $400.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $402.14.
View Our Latest Stock Report on ONC
Institutional Investors Weigh In On BeOne Medicines
Several institutional investors have recently modified their holdings of the business. EFG International AG bought a new stake in BeOne Medicines in the 4th quarter worth about $25,000. Leonteq Securities AG bought a new position in BeOne Medicines during the 4th quarter valued at about $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the 2nd quarter valued at about $35,000. CWM LLC boosted its holdings in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the 4th quarter valued at about $61,000. 48.55% of the stock is owned by hedge funds and other institutional investors.
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
